Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 08.04.2024 1 Acad Radiol 1 Acta Cytol 1 Acta Pharm 3 Actas Urol Esp (Engl Ed) 1 Adv Healthc Mater 2 Ann Surg Oncol 1 Asia Pac J Clin Oncol 1 Asian J Endosc Surg 6 Asian J Surg 1 Biochem Pharmacol 1 BMJ Open 1 Cancer Cell Int 1 Cancer Epidemiol Biomarkers Prev 3 Cancer Med 1 Cell Mol Biol Lett 1 Cell Signal 1 Clin Genitourin Cancer 1 Curr Opin Oncol 1 Eur J Epidemiol 1 Eur Rev Med Pharmacol Sci 1 Eur Urol Oncol 1 Eur Urol Open Sci 1 Heliyon 1 Int Urol Nephrol 1 Int Wound J 1 J Cancer Res Clin Oncol 1 J Endourol 1 J Exp Clin Cancer Res 1 J Immunoassay Immunochem 1 J Med Econ 3 J Natl Compr Canc Netw 1 J Robot Surg 1 J Thromb Haemost 1 JCO Precis Oncol 1 Mayo Clin Proc 1 Medicine (Baltimore) 1 Mol Cancer Ther 1 Mymensingh Med J 1 Nat Commun 1 Naunyn Schmiedebergs Arch Pharmacol 1 Oncol Res 1 PLoS One 1 Target Oncol 2 Urol Int 3 Urol Oncol 1 Urologia 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acad Radiol

1. CAO Y, Zhu H, Li Z, Liu C, et al
   CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients.
   Acad Radiol. 2024 Mar 30:S1076-6332(24)00138-7. doi: 10.1016/j.acra.2024.
   PubMed         Abstract available
   
   

   
   Acta Cytol

2. TANAKA S, Tokuhara Y, Ariyasu S, Morinishi T, et al
   Diagnostic Immunocytostaining with Peroxisome Proliferator-Activated Receptor-Gamma in Urine Cytology Samples.
   Acta Cytol. 2024;68:60-65.
   PubMed         Abstract available
   
   

   
   Acta Pharm

3. JAIN NK, Tailang M, Thangavel N, Makeen HA, et al
   A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
   Acta Pharm. 2024;74:1-36.
   PubMed         Abstract available
   
   

   
   Actas Urol Esp (Engl Ed)

4. TORIBIO-VAZQUEZ C, Gomez Rivas J, Amigo F, Carrion DM, et al
   Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study.
   Actas Urol Esp (Engl Ed). 2024;48:228-237.
   PubMed         Abstract available
   
   
5. MONTOSA RODENAS P, Gomez Huertas M, Perez Rosillo MA, Lainez Ramos-Bossini AJ, et al
   Intravesical fat-fluid level as a warning sign of contained bladder perforation: Correlation between cystoscopy and computed tomography findings.
   Actas Urol Esp (Engl Ed). 2024;48:254-256.
   PubMed        
   
   
6. LOPEZ VALCARCEL M, Barrado Los Arcos M, Ferri Molina M, Cienfuegos Belmonte I, et al
   Is trimodal therapy the current standard for muscle-invasive bladder cancer?
   Actas Urol Esp (Engl Ed). 2024 Apr 2:S2173-5786(24)00028.
   PubMed         Abstract available
   
   

   
   Adv Healthc Mater

7. HOHAGEN M, Sanchez L, Herbst AJ, Kahlig H, et al
   MANNosylation of Mesoporous Silica Nanoparticles Modifies TLR4 Localization and NF-kappaB Translocation in T24 Bladder Cancer Cells.
   Adv Healthc Mater. 2024 Mar 30:e2304150. doi: 10.1002/adhm.202304150.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

8. OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
   ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer.
   Ann Surg Oncol. 2024 Apr 2. doi: 10.1245/s10434-024-15122.
   PubMed        
   
   
9. SLUSARCZYK A, Ismail H, Zapala L, Piecha T, et al
   Changes in the Urinary Microbiome After Transurethral Resection of Non-muscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
   Ann Surg Oncol. 2024 Apr 3. doi: 10.1245/s10434-024-15198.
   PubMed         Abstract available
   
   

   
   Asia Pac J Clin Oncol

10. COLAK R, Erdem GU, Kapar C, Gulturk I, et al
    Change in the neutrophil-lymphocyte ratio may predict early recurrence in operated bladder cancer.
    Asia Pac J Clin Oncol. 2024 Apr 4. doi: 10.1111/ajco.14065.
    PubMed         Abstract available
    
    

    
    Asian J Endosc Surg

11. KADORIKU F, Sasaki Y, Fukuta K, Nishiyama M, et al
    Robot-assisted intracorporeal ileal conduit urinary diversion: A two-center comparative study of Bricker versus Wallace ureteroileal anastomosis.
    Asian J Endosc Surg. 2024;17:e13307.
    PubMed         Abstract available
    
    

    
    Asian J Surg

12. CHEN BH, Hsieh SJ, Chiu B
    Non-functional bladder paraganglioma with urinary frequency: A case report.
    Asian J Surg. 2024;47:1990-1991.
    PubMed        
    
    
13. ZHANG KY, Hu JS, Liu XH
    Efficacy and safety of robot-assisted total cystectomy: A systematic review and meta-analysis.
    Asian J Surg. 2024;47:2028-2032.
    PubMed        
    
    
14. FENG X, Chen Z
    Case report and literature review of penile metastasis of bladder cancer.
    Asian J Surg. 2024 Mar 29:S1015-9584(24)00529.
    PubMed        
    
    
15. XIN JH, Jiang B, Yuan YH, Zou XF, et al
    Primary diffuse large B-cell lymphoma of the urinary bladder: A case report.
    Asian J Surg. 2024;47:1930-1931.
    PubMed        
    
    
16. HUANG P, Xin JH, Zou XF, Wu GQ, et al
    Isolated myeloid sarcoma in the urinary bladder: A cases report.
    Asian J Surg. 2024;47:1928-1929.
    PubMed        
    
    
17. SU BY, Tan H, Bao JS, He QQ, et al
    Obstructive ureteral calculi and upper-tract urothelial carcinoma: A tale of two cases.
    Asian J Surg. 2024;47:1825-1826.
    PubMed        
    
    

    
    Biochem Pharmacol

18. DING X, Jin Y, Shi X, Wang Y, et al
    TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling.
    Biochem Pharmacol. 2024 Mar 27:116172. doi: 10.1016/j.bcp.2024.116172.
    PubMed         Abstract available
    
    

    
    BMJ Open

19. LABIDI S, Meti N, Barua R, Li M, et al
    Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
    BMJ Open. 2024;14:e081480.
    PubMed         Abstract available
    
    

    
    Cancer Cell Int

20. CAI T, Feng T, Li G, Wang J, et al
    Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75.
    Cancer Cell Int. 2024;24:125.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

21. ROSSER CJ
    Assessing the Causal Relationship between Waterpipe Smoking and Bladder Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024;33:461-462.
    PubMed         Abstract available
    
    

    
    Cancer Med

22. WASHINGTON SL 3RD, Lonergan PE, Odisho AY, Meng MV, et al
    Association of household net worth with healthcare costs after radical cystectomy using real-world data.
    Cancer Med. 2024;13:e7116.
    PubMed         Abstract available
    
    
23. AHMADI S, Ambite I, Brisuda A, Hacek J, et al
    Similar immune responses to alpha1-oleate and Bacillus Calmette-Guerin treatment in patients with bladder cancer.
    Cancer Med. 2024;13:e7091.
    PubMed         Abstract available
    
    
24. MEAGHER M, Krause H, Elliott A, Farrell A, et al
    Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinoma.
    Cancer Med. 2024;13:e7148.
    PubMed         Abstract available
    
    

    
    Cell Mol Biol Lett

25. LIN M, Xu X, Zhou X, Feng H, et al
    Sialylation on vesicular integrin beta1 determined endocytic entry of small extracellular vesicles into recipient cells.
    Cell Mol Biol Lett. 2024;29:46.
    PubMed         Abstract available
    
    

    
    Cell Signal

26. JI Q, Ma F, Zhang X, Liu Y, et al
    Hsa_circ_0005320 affects cell proliferation and the cell cycle via the IGF2BP3/CDK2 axis in bladder cancer.
    Cell Signal. 2024 Mar 31:111154. doi: 10.1016/j.cellsig.2024.111154.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

27. MONTGOMERY J, Lybbert D, Sana S, El-Zawahry A, et al
    Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guerin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previo
    Clin Genitourin Cancer. 2024;22:102059.
    PubMed         Abstract available
    
    

    
    Curr Opin Oncol

28. NIGLIO SA, Purswani JM, Schiff PB, Lischalk JW, et al
    Organ preservation in muscle-invasive urothelial bladder cancer.
    Curr Opin Oncol. 2024;36:155-163.
    PubMed         Abstract available
    
    

    
    Eur J Epidemiol

29. VERMEULEN R, Bodinier B, Dagnino S, Wada R, et al
    A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer.
    Eur J Epidemiol. 2024 Mar 30. doi: 10.1007/s10654-024-01110.
    PubMed         Abstract available
    
    

    
    Eur Rev Med Pharmacol Sci

30. JIANG SC, Liao YG, Luo J, Hu D, et al
    Comparison of intravesical chemotherapy regimens after radical nephroureterectomy for upper tract urothelial carcinoma and analysis of risk factors for postoperative recurrence.
    Eur Rev Med Pharmacol Sci. 2024;28:2387-2395.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

31. ACHARD V, Fournier B, D'Haese D, Krzystyniak J, et al
    Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Tri
    Eur Urol Oncol. 2024 Mar 30:S2588-9311(24)00084.
    PubMed         Abstract available
    
    

    
    Eur Urol Open Sci

32. SCHROECK FR, Grubb R, MacKenzie TA, Ould Ismail AA, et al
    Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surv
    Eur Urol Open Sci. 2024;63:19-30.
    PubMed         Abstract available
    
    

    
    Heliyon

33. HUANG Y, Lv Y, Yang B, Zhang S, et al
    Enhancing m(6)A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer.
    Heliyon. 2024;10:e28165.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

34. BERNARDINO RM, Wettstein M, Garisto J, Fleshner NE, et al
    Editorial comment to the paper: RE: low cubilin/myeloperoxidase's ratio as a promising biomarker for prognosis of high grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Apr 2. doi: 10.1007/s11255-024-04035.
    PubMed        
    
    

    
    Int Wound J

35. LUO HM, Xiong YJ
    Comparing surgical site wound infection after laparoscopic and open radical cystectomies in patients with bladder cancer.
    Int Wound J. 2024;21:e14718.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

36. LEE S, Yoon Y, Suh J, You D, et al
    Association of preoperative sarcopenia with the long-term prognosis of patients with bladder cancer undergoing radical cystectomy.
    J Cancer Res Clin Oncol. 2024;150:173.
    PubMed         Abstract available
    
    

    
    J Endourol

37. SIMHAL RK, Simon DP, Wang KR, Shah YB, et al
    Perioperative and Complication Related Outcomes for Robotic-Assisted vs Open Radical Cystectomy: A Comparative National Surgical Quality Improvement Project Analysis.
    J Endourol. 2024;38:331-339.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

38. ZHOU J, Zhou R, Zhu Y, Deng S, et al
    Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity.
    J Exp Clin Cancer Res. 2024;43:101.
    PubMed         Abstract available
    
    

    
    J Immunoassay Immunochem

39. BEN REJEB S, Kouki N, Ben Ghachem D, Khouni H, et al
    Prognostic significance of E-Cadherin and B-Catenin in non-muscle invasive bladder cancer.
    J Immunoassay Immunochem. 2024 Apr 1:1-10. doi: 10.1080/15321819.2024.2335154.
    PubMed         Abstract available
    
    

    
    J Med Econ

40. BRODTKORB TH, Knight C, Kamgar F, Teitsson S, et al
    Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
    J Med Econ. 2024;27:543-553.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

41. AVUDAIAPPAN AP, Prabhakar P, Eldefrawy A, Caso J, et al
    CLO24-074: Impact of Neoadjuvant Chemotherapy on Survival and Pathological Response Among Octogenarians Who Underwent Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2024;22.
    PubMed        
    
    
42. AVUDAIAPPAN AP, Prabhakar P, Chundru S, Renshaw A, et al
    CLO24-064: Evaluation of the Reliability of mpMRI in Diagnosing Prostate Cancer Following Intravesical Bacillus Calmette Guerin Therapy for Bladder Cancer.
    J Natl Compr Canc Netw. 2024;22.
    PubMed        
    
    
43. LIYANAGE T, Liyanage AH
    QIM24-194: A Cost Effective, Noninvasive Mutiomics Assay (BCDx) for Diagnostic Accuracy of Bladder Cancer Compares to the Gold Standard of Cytoscopy and Cytology.
    J Natl Compr Canc Netw. 2024;22.
    PubMed        
    
    

    
    J Robot Surg

44. SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
    Impact of lymph node dissection on surgical and oncological outcomes in patients undergoing robot-assisted radical cystectomy for bladder cancer: a multicenter retrospective study.
    J Robot Surg. 2024;18:141.
    PubMed         Abstract available
    
    

    
    J Thromb Haemost

45. CHEN Y, Jiao W, Wang Y, Liang Z, et al
    MITD1 deficiency leads to poor survival via tissue factor-mediated coagulation in bladder cancer.
    J Thromb Haemost. 2024 Mar 28:S1538-7836(24)00173.
    PubMed         Abstract available
    
    

    
    JCO Precis Oncol

46. PILALA KM, Kotronopoulos G, Levis P, Giagkos GC, et al
    MIR145 Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome.
    JCO Precis Oncol. 2024;8:e2300414.
    PubMed         Abstract available
    
    

    
    Mayo Clin Proc

47. TEKIN B, Erickson LA, Gupta S
    Secondary Involvement of the Urinary Bladder by Endometrial Carcinoma.
    Mayo Clin Proc. 2024;99:680-682.
    PubMed        
    
    

    
    Medicine (Baltimore)

48. PAN W, Liu X, Liu S
    ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
    Medicine (Baltimore). 2024;103:e37590.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

49. NISHIYAMA H, Yonese J, Kawahara T, Matsumoto R, et al
    TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naive Locally Advanced or Metastatic Urothelial Carcinoma.
    Mol Cancer Ther. 2024;23:532-540.
    PubMed         Abstract available
    
    

    
    Mymensingh Med J

50. NAHAR R, Jinnah MSA, Karim SS, Alam MM, et al
    Expression of Cyclin D1 in Urothelial Carcinoma of Urinary Bladder and its Association with Tumour Grade.
    Mymensingh Med J. 2024;33:461-465.
    PubMed         Abstract available
    
    

    
    Nat Commun

51. CHENG M, Chen S, Li K, Wang G, et al
    CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.
    Nat Commun. 2024;15:2818.
    PubMed         Abstract available
    
    

    
    Naunyn Schmiedebergs Arch Pharmacol

52. ZHANG W, Wang Y, Tang Q, Li Z, et al
    PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway.
    Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 4. doi: 10.1007/s00210-024-03061.
    PubMed         Abstract available
    
    

    
    Oncol Res

53. YADOLLAHVANDMIANDOAB R, Jalalizadeh M, Dionato FAV, Buosi K, et al
    Clinical implications of single cell sequencing for bladder cancer.
    Oncol Res. 2024;32:597-605.
    PubMed         Abstract available
    
    

    
    PLoS One

54. 
    Retraction: SATB1 Overexpression Regulates the Development and Progression in Bladder Cancer through EMT.
    PLoS One. 2024;19:e0301572.
    PubMed        
    
    

    
    Target Oncol

55. LEARY JB, Enright T, Bakaloudi DR, Basnet A, et al
    Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
    Target Oncol. 2024 Apr 3. doi: 10.1007/s11523-024-01056.
    PubMed         Abstract available
    
    

    
    Urol Int

56. GARAZ R, Stuhler V, Stenzl A, Rottscholl R, et al
    Hemangioma of the Urinary Bladder: A Brief Narrative Review of Their Diagnosis, Histology, and Treatment Options.
    Urol Int. 2024;108:83-88.
    PubMed         Abstract available
    
    
57. WALACH MT, Nitschke K, Gross-Weege M, Grosshans J, et al
    Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma.
    Urol Int. 2024;108:128-136.
    PubMed         Abstract available
    
    

    
    Urol Oncol

58. STANIORSKI CJ, Yu M, Sharbaugh D, Stencel MG, et al
    Predictors of persistent opioid use in bladder cancer patients undergoing radical cystectomy: A SEER-Medicare analysis.
    Urol Oncol. 2024 Apr 1:S1078-1439(24)00362-4. doi: 10.1016/j.urolonc.2024.
    PubMed         Abstract available
    
    
59. PORTEN SP, Wang EY, Vohra P, Carroll PR, et al
    Evaluation of URO17(R) to improve non-invasive detection of bladder cancer.
    Urol Oncol. 2024 Mar 28:S1078-1439(24)00345.
    PubMed         Abstract available
    
    
60. LI L, Zhang J, Zhe X, Tang M, et al
    Prediction of histopathologic grades of bladder cancer with radiomics based on MRI: Comparison with traditional MRI.
    Urol Oncol. 2024 Mar 30:S1078-1439(24)00338.
    PubMed         Abstract available
    
    

    
    Urologia

61. BIZZARRI FP, Scarciglia E, Russo P, Marino F, et al
    Elderly and bladder cancer: The role of radical cystectomy and orthotopic urinary diversion.
    Urologia. 2024 Mar 29:3915603241240644. doi: 10.1177/03915603241240644.
    PubMed         Abstract available
    
    

    
    World J Urol

62. SWINTON M, Devi A, Song YP, Hoskin P, et al
    Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer.
    World J Urol. 2024;42:210.
    PubMed         Abstract available
    
    
63. LIN YH, Tsai HY, Wu CT
    From TURP to enucleation: navigating the complex relationship between BPH treatments and bladder cancer.
    World J Urol. 2024;42:203.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.